MX2018003452A - Composiciones de taxano orales y metodos. - Google Patents

Composiciones de taxano orales y metodos.

Info

Publication number
MX2018003452A
MX2018003452A MX2018003452A MX2018003452A MX2018003452A MX 2018003452 A MX2018003452 A MX 2018003452A MX 2018003452 A MX2018003452 A MX 2018003452A MX 2018003452 A MX2018003452 A MX 2018003452A MX 2018003452 A MX2018003452 A MX 2018003452A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
surfactant
polysorbate
surfactants
absorption
Prior art date
Application number
MX2018003452A
Other languages
English (en)
Inventor
Li Yoon Weng
Yiu- Nam Lau Johnson
So Bik Chan Denise
Tsung Lee Ming
Original Assignee
Athenex Hk Innovative Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Hk Innovative Ltd filed Critical Athenex Hk Innovative Ltd
Publication of MX2018003452A publication Critical patent/MX2018003452A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una composición farmacéutica que comprende un taxano (por ejemplo, paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel y/o tesetaxel) en una mezcla de primero y segundo tensioactivos. La absorción del taxano se incrementa a partir de la composición farmacéutica y es mayor que la suma de la absorción de docetaxel a partir de ya sea el primero o el segundo tensioactivos. El incremento en la absorción se incrementa especialmente cuando la relación del primer tensioactivo respecto al segundo tensioactivo en la composición farmacéutica está entre 60:40 y 85:15 en peso, y el peso de tensioactivo total no excede 98% del peso total. El polisorbato 80, polisorbato 20 y polioxilglicéridos de caprilocaproilo sirven como primeros tensioactivos adecuados y polisorbato 80 o aceite de ricino polietoxilado sirven como segundos tensioactivos adecuados. La estabilidad de la composición farmacéutica se puede incrementar al incluir adicionalmente un estabilizante (por ejemplo, ácido cítrico y/o ácido ascórbico).
MX2018003452A 2015-09-30 2016-09-29 Composiciones de taxano orales y metodos. MX2018003452A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234868P 2015-09-30 2015-09-30
PCT/CN2016/100807 WO2017054754A1 (en) 2015-09-30 2016-09-29 Oral taxane compositions and methods

Publications (1)

Publication Number Publication Date
MX2018003452A true MX2018003452A (es) 2018-09-06

Family

ID=58408671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003452A MX2018003452A (es) 2015-09-30 2016-09-29 Composiciones de taxano orales y metodos.

Country Status (13)

Country Link
US (2) US10835511B2 (es)
EP (1) EP3355881B1 (es)
JP (2) JP6985276B2 (es)
KR (1) KR102656954B1 (es)
CN (2) CN113521002B (es)
AU (2) AU2016333292B2 (es)
BR (1) BR112018006510A2 (es)
CA (1) CA2999201C (es)
ES (1) ES2904691T3 (es)
HK (1) HK1258390A1 (es)
MX (1) MX2018003452A (es)
TW (2) TWI752750B (es)
WO (1) WO2017054754A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752750B (zh) * 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US10188626B2 (en) * 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
EP3773581A4 (en) * 2018-04-13 2021-12-29 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
EP3793523A1 (en) * 2018-05-15 2021-03-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
US20220008566A1 (en) * 2018-10-12 2022-01-13 Advanced Accelerator Applications International Sa Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant
TW202038934A (zh) * 2018-12-14 2020-11-01 香港商慧源香港創新有限公司 用於治療癌症之口服投予多西紫杉醇（ｄｏｃｅｔａｘｅｌ）和Ｐ－ｇｐ抑制劑的醫療組合
CN116964044A (zh) 2020-10-07 2023-10-27 希华医药有限公司 乙酰胺基-苯基四唑衍生物及其使用方法
CN116350619A (zh) * 2021-12-28 2023-06-30 北京抗创联生物制药技术研究有限公司 一种口服紫杉烷类药物组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999049848A1 (en) * 1998-04-01 1999-10-07 Rtp Pharma Inc. Anticancer compositions
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
BR0215184A (pt) * 2001-12-20 2006-06-06 Bristol Myers Squibb Co composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
EP2138164A1 (en) 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US20070085067A1 (en) 2005-10-18 2007-04-19 Lewis John R Gated parking corral
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
EP2170319A4 (en) 2007-06-22 2011-10-12 Scidose Llc SOLVENT FORMULATION FROM DOCETAXEL WITHOUT TWEEN 80
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
RU2603833C2 (ru) * 2010-11-08 2016-11-27 Кадила Фармасьютикалз Лимитед Фармацевтическая композиция таксоидов
WO2012176434A1 (ja) 2011-06-22 2012-12-27 富士フイルム株式会社 撮像レンズおよび撮像装置
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI752750B (zh) * 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法

Also Published As

Publication number Publication date
AU2022200919A1 (en) 2022-03-03
EP3355881B1 (en) 2021-12-08
CN113521002A (zh) 2021-10-22
US11963942B2 (en) 2024-04-23
BR112018006510A2 (pt) 2018-10-09
AU2016333292B2 (en) 2021-11-11
EP3355881A4 (en) 2019-05-08
JP6985276B2 (ja) 2021-12-22
US20210023042A1 (en) 2021-01-28
JP2018529778A (ja) 2018-10-11
CA2999201C (en) 2024-02-06
CN108697683B (zh) 2021-09-17
CA2999201A1 (en) 2017-04-06
TW202227048A (zh) 2022-07-16
AU2022200919B2 (en) 2024-03-07
US20170087121A1 (en) 2017-03-30
AU2016333292A1 (en) 2018-04-12
WO2017054754A1 (en) 2017-04-06
JP7227334B2 (ja) 2023-02-21
KR20180093880A (ko) 2018-08-22
HK1258390A1 (zh) 2019-11-08
TW201711680A (zh) 2017-04-01
ES2904691T3 (es) 2022-04-05
EP3355881A1 (en) 2018-08-08
TWI715636B (zh) 2021-01-11
KR102656954B1 (ko) 2024-04-12
TW202114653A (zh) 2021-04-16
US10835511B2 (en) 2020-11-17
CN108697683A (zh) 2018-10-23
CN113521002B (zh) 2022-12-13
TWI752750B (zh) 2022-01-11
JP2022016636A (ja) 2022-01-21

Similar Documents

Publication Publication Date Title
MX2018003452A (es) Composiciones de taxano orales y metodos.
MX2018002999A (es) Composiciones de inoculante estables y metodos para producir las mismas.
EA200801132A1 (ru) Новые улучшенные композиции для лечения рака
MX2017015304A (es) Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa.
JP2018529778A5 (es)
PH12015501354A1 (en) Antiviral compounds
NZ707551A (en) Prostacyclin compositions and methods for using the same
NZ723838A (en) Cannabinoid compositions and uses
ES2721530T3 (es) Uso de acetato de cis- o trans-(2-isobutil-4-metil-tetrahidropiran-4-ilo) isoméricamente puro o altamente enriquecido con isómeros
MX357914B (es) Composiciones y articulos para el cuidado personal.
BR112019001852A2 (pt) composição de cannabis
DOP2016000007A (es) Pirazolpiridinas sustituidas
WO2014053401A3 (en) Method of improving plant health
NZ603828A (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
MX2017009945A (es) Composiciones de perfume.
EA201400839A1 (ru) Фотостабильная солнцезащитная композиция
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
PH12015500681A1 (en) Non-aqueous taxane nanodispersion formulations and methods of using the same
DE60327651D1 (de) Thio-analoga von paclitaxel und deren vorprodukte
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
WO2011097149A3 (en) Taxane-and taxoid-protein compositions
PE20180488A1 (es) Composiciones farmaceuticas solidas para el tratamiento del vhc
MX2015009615A (es) Uso de 4,8-dimetil-3,7-nonadien-2-ol como perfume.